Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
IPO Year:
Exchange: NYSE
Website: stryker.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
5/30/2024 | $372.00 | Neutral | Goldman |
5/22/2024 | $392.00 | Hold → Buy | Needham |
1/31/2024 | $315.00 → $360.00 | Hold → Buy | Canaccord Genuity |
10/20/2023 | $345.00 | Buy | ROTH MKM |
9/5/2023 | $310.00 → $315.00 | Neutral → Buy | BofA Securities |
3/29/2023 | $287.00 | Neutral | UBS |
1/25/2023 | Sector Weight | KeyBanc Capital Markets | |
1/9/2023 | $240.00 → $284.00 | Sector Perform → Outperform | RBC Capital Mkts |
11/1/2022 | $225.00 → $220.00 | Buy → Hold | Canaccord Genuity |
10/18/2022 | $239.00 | Overweight | Barclays |
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
Portage, Michigan, May 09, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.80 per share payable July 31, 2024 to shareholders of record at the close of business on June 28, 2024, representing an increase of 6.7% versus the prior year and unchanged from the previous quarter. About Stryker Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryk
Portage, Michigan, April 30, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2024: First Quarter Results Reported net sales increased 9.7% to $5.2 billionOrganic net sales increased 10.0%Reported operating income margin of 18.5%Adjusted operating income margin(1) increased 80 bps to 21.9%Reported EPS increased 33.1% to $2.05Adjusted EPS(1) increased 16.8% to $2.50 First Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology 11.5 % (0.5) % 12.0 % 0.4 % 11.6
Portage, Michigan, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.80 per share payable April 30, 2024 to shareholders of record at the close of business on March 29, 2024, representing an increase of 6.7% versus the prior year and unchanged from the previous quarter. About Stryker Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker im
Portage, Michigan, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the fourth quarter and full year of 2023: Fourth Quarter Results Reported net sales increased 11.8% to $5.8 billionOrganic net sales increased 11.4%Reported operating income margin of 21.6%Adjusted operating income margin(1) increased 60 bps to 27.2%Reported EPS increased 102.7% to $2.98Adjusted EPS(1) increased 15.3% to $3.46 Fourth Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology 12.3 % 0.3 % 12.0 % 0.2 %
Kalamazoo, Michigan, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.80 per share payable January 31, 2024 to shareholders of record at the close of business on December 29, 2023, representing an increase of 6.7% versus the prior year and previous quarter. "We continue to deliver strong growth and solid financial performance, and aligning with our capital allocation strategy we are raising our dividend 6.7%," said Kevin Lobo, Chair and Chief Executive Officer. Stryker is one of the world's leading medical technology companies and, together with its customers, is driven to make healthcare better
Kalamazoo, Michigan, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the third quarter of 2023: Third Quarter Results Reported net sales increased 9.6% to $4.9 billionOrganic net sales increased 9.2%Reported operating income margin of 19.0%Adjusted operating income margin(1) increased 110 bps to 23.4%Reported EPS decreased 15.9% to $1.80 Adjusted EPS(1) increased 16.0% to $2.46 Third Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology 10.5 % 0.2 % 10.3 % 0.2 % 10.1 %Orthop
Kalamazoo, Michigan, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the second quarter of 2023: Second Quarter Results Reported net sales increased 11.2% to $5.0 billionOrganic net sales increased 11.9%Reported operating income margin of 19.3%Adjusted operating income margin(1) increased 60 bps to 24.3%Reported EPS increased 12.2% to $1.93Adjusted EPS(1) increased 12.9% to $2.54 Second Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology 12.2 % (0.7) % 12.9 % — % 12.9
Kalamazoo, Michigan, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.75 per share payable October 31, 2023 to shareholders of record at the close of business on September 29, 2023, representing an increase of 7.9% versus the prior year and unchanged from the previous quarter. Stryker is one of the world's leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Medical and Surgical, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around
Kalamazoo, Michigan, May 10, 2023 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.75 per share payable July 31, 2023 to shareholders of record at the close of business on June 30, 2023, representing an increase of 7.9% versus the prior year and unchanged from the previous quarter. Stryker is one of the world's leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Medical and Surgical, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the wor
KALAMAZOO, Michigan, USA, May 2, 2023 /PRNewswire/ -- Stryker (NYSE:SYK), one of the world's leading medical technology companies, announced today that it has completed the acquisition of Cerus Endovascular Ltd., a privately held, commercial-stage, medical device company engaged in the design and development of neurointerventional devices for the treatment of intracranial aneurysms. Cerus Endovascular's CE Marked products, the Contour Neurovascular System and the Neqstent Coil Assisted Flow Diverter, will expand Stryker's current portfolio of aneurysm treatment solutions. Ceru
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
Stryker (NYSE:SYK) has outperformed the market over the past 10 years by 4.1% on an annualized basis producing an average annual return of 15.02%. Currently, Stryker has a market capitalization of $127.79 billion. Buying $100 In SYK: If an investor had bought $100 of SYK stock 10 years ago, it would be worth $401.97 today based on a price of $335.44 for SYK at the time of writing. Stryker's Performance Over Last 10 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewed by
Ratings for Stryker (NYSE:SYK) were provided by 14 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 7 2 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 0 1 0 0 3M Ago 4 6 1 0 0 Analysts have set 12-month price targets for Stryker, revealing an average target of $378.57, a high estimate of $405.00, and a low estimate of $351.00. This current average has increased by 5.25% from the previous
Evercore ISI Group analyst Vijay Kumar maintains Stryker (NYSE:SYK) with a Outperform and lowers the price target from $370 to $365.
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. Here's the list of options activity happening in today's session: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume PFE CALL SWEEP BEARISH 07/19/24 $28.00 $74.9K 29.5K 5.7K ZTS CALL SWEEP BEARISH 07/19/24 $170.00 $39.
Stryker (NYSE:SYK) has outperformed the market over the past 10 years by 4.28% on an annualized basis producing an average annual return of 15.2%. Currently, Stryker has a market capitalization of $132.83 billion. Buying $100 In SYK: If an investor had bought $100 of SYK stock 10 years ago, it would be worth $408.95 today based on a price of $348.67 for SYK at the time of writing. Stryker's Performance Over Last 10 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewed by
Artelon is a privately held company specializing in innovative soft tissue fixation products for foot and ankle and sports medicine procedures. The acquisition will strengthen Stryker's offerings in the soft tissue fixation segment and highlights Stryker's commitment to providing differentiated solutions for ligament and tendon reconstruction.
Ratings for Stryker (NYSE:SYK) were provided by 14 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 6 6 2 0 0 Last 30D 0 0 1 0 0 1M Ago 4 4 1 0 0 2M Ago 2 2 0 0 0 3M Ago 0 0 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Stryker, presenting an average target of $381.5, a high estimate of $406.00, and a low estimate of $351.00. This current average reflects an
Goldman Sachs analyst David Roman initiates coverage on Stryker (NYSE:SYK) with a Neutral rating and announces Price Target of $372.
Stryker (NYSE:SYK) has outperformed the market over the past 15 years by 3.14% on an annualized basis producing an average annual return of 15.27%. Currently, Stryker has a market capitalization of $129.33 billion. Buying $1000 In SYK: If an investor had bought $1000 of SYK stock 15 years ago, it would be worth $8,298.44 today based on a price of $339.50 for SYK at the time of writing. Stryker's Performance Over Last 15 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewe
Needham analyst Mike Matson upgraded Stryker Corp (NYSE:SYK) from Hold to Buy and a $392 price target. Matson expects new product launches combined with SYK’s capital equipment backlog to allow it to deliver upside to consensus revenue estimates and overcome any potential recon market slowdown. SYK expects significant margin improvement in 2024-2025. The analyst expects revenue upside to translate into EPS upside. SYK also expects to increase its M&A activity, and Matson expects deals to serve as positive catalysts. Considering its double-digit organic revenue growth potential, Matson noted that SYK shares are attractive. The analyst expects new product launches and SYK’s
SD - STRYKER CORP (0000310764) (Filer)
8-K - STRYKER CORP (0000310764) (Filer)
10-Q - STRYKER CORP (0000310764) (Filer)
8-K - STRYKER CORP (0000310764) (Filer)
DEFA14A - STRYKER CORP (0000310764) (Filer)
DEF 14A - STRYKER CORP (0000310764) (Filer)
10-K - STRYKER CORP (0000310764) (Filer)
8-K - STRYKER CORP (0000310764) (Filer)
CERT - STRYKER CORP (0000310764) (Filer)
8-A12B - STRYKER CORP (0000310764) (Filer)
Goldman initiated coverage of Stryker with a rating of Neutral and set a new price target of $372.00
Needham upgraded Stryker from Hold to Buy and set a new price target of $392.00
Canaccord Genuity upgraded Stryker from Hold to Buy and set a new price target of $360.00 from $315.00 previously
ROTH MKM initiated coverage of Stryker with a rating of Buy and set a new price target of $345.00
BofA Securities upgraded Stryker from Neutral to Buy and set a new price target of $315.00 from $310.00 previously
UBS initiated coverage of Stryker with a rating of Neutral and set a new price target of $287.00
KeyBanc Capital Markets initiated coverage of Stryker with a rating of Sector Weight
RBC Capital Mkts upgraded Stryker from Sector Perform to Outperform and set a new price target of $284.00 from $240.00 previously
Canaccord Genuity downgraded Stryker from Buy to Hold and set a new price target of $220.00 from $225.00 previously
Barclays initiated coverage of Stryker with a rating of Overweight and set a new price target of $239.00
Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m
Spineology Inc. ("Spineology" or the "Company"), the leader in ultra-minimally invasive spine surgery, announced today the addition of Emory Rooney as Executive Vice President, Sales. In this role, Rooney will lead U.S. market growth and sales efforts. Rooney comes to Spineology with extensive spine sales experience, having served in Medical Device fields related to spinal implants and navigation for nearly 20 years. "The addition of Emory adds even further conviction about our clear opportunity for growth at Spineology," said Brian Snider, Chief Executive Officer at Spineology. "I have had the opportunity to work with Emory and have seen his impact leading sales teams, building new terri
PALM BEACH GARDENS, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- AeroClean Technologies ("AeroClean" or the "Company") (NASDAQ:AERC), a pathogen elimination technology company harnessing patented UV-C LED technology with Pūrgo™ to significantly reduce and remove harmful pathogens to keep work, play and life going, today announced the appointment of Timothy J. Scannell, former President and Chief Operating Officer at Stryker, to its Board of Directors (the "Board"). On May 11, 2022, the Board appointed Mr. Scannell as a new director on the Board, chair of the Nominating and Corporate Governance Committee and a member of the Compensation Committee. Mr. Scannell brings over 30 years of experienc
FREMONT, Calif., Sept. 1, 2021 /PRNewswire/ -- THINK Surgical, Inc., an innovator in the field of orthopedic surgical robots, today announced the appointment of Stuart F. Simpson as its president and chief executive officer. Mr. Simpson's decades of experience in the medical device industry, particularly his deep understanding of the orthopedics industry and orthopedic surgical robots, makes him the ideal person to lead THINK Surgical. Mr. Simpson had a successful 24-year career at Stryker Corporation (NYSE:SYK) holding roles of increasing responsibility in Europe, Asia Paci
As the pioneer of the first FDA-approved continuous glucose monitor, Dr. Mastrototaro will be integral in advancing the development and regulatory process of the Company's glucose and blood pressure monitoring technology PLEASANTON, CA / ACCESSWIRE / March 25, 2021 / Today, Movano Inc. (NASDAQ:MOVE), a health technology company designing devices that empower individuals to optimize their health in order to prevent and better manage chronic diseases, announced current Director, Dr. John Mastrototaro, will join the Company as CEO, effective April 1, 2021. Movano's founder and current CEO, Michael Leabman, will become the Company's CTO and will remain on the Company's Board of Directors. Dr. M
WARREN, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced the appointment of Julie Krop, M.D., Chief Medical Officer of Freeline Therapeutics (NASDAQ: FRLN), and Marco Taglietti, M.D., Director, President and Chief Executive Officer of SCYNEXIS (NASDAQ: SCYX), to the Board of Directors of the Company effective February 10, 2021. Aquestive also announced the resignation of Douglas K. Bratton from the Board of Directors after more than 17 years of service. Aquestive’s Board of Directors
Kalamazoo, Michigan, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.63 per share payable January 29, 2021 to shareholders of record at the close of business on December 31, 2020, representing an increase of 9.6% versus the prior year and previous quarter. “We continue to drive solid financial results in a challenging environment, and consistent with our stated capital allocation philosophy, are raising our dividend 9.6%," said Kevin Lobo, Chairman and Chief Executive Officer. Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healt
Stryker (NYSE:SYK), a global leader in medical technologies, has completed the previously announced acquisition of Artelon, a privately held company specializing in innovative soft tissue fixation products for foot and ankle and sports medicine procedures. "Integrating Artelon's portfolio into Stryker's offerings will allow us to deliver best-in-class soft tissue fixation solutions," said Tim Lanier, president of Stryker's Trauma & Extremities division. "This acquisition strengthens our competitive edge. Leveraging Artelon's unique synthetic technology and extensive expertise positions us to continue driving innovation and solidify our leadership in the foot and ankle and sports medicine
Portage, Michigan, July 01, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for first quarter of fiscal year 2024 on Tuesday, July 30, 2024. A press release will be issued at approximately 4:05pm ET and available at Stryker - Press Releases that day. The press release will include summary financial information for the company's second quarter of fiscal year 2024, that ended June 30, 2024. Stryker will host a webcast at 4:30pm ET on Tuesday, July 30, to discuss results for its second quarter fiscal year 2024. The webcast can be accessed at Stryker - Events & Presentations. An archive of the webcast will also be available on the company's webs
Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m
PORTAGE, Michigan and CHARLOTTE, North Carolina, USA, June 18, 2024 /PRNewswire/ -- Stryker is bringing its innovative products, platforms and robotic technologies to IRCAD North America (IRCAD NA), a subsidiary of Atrium Health, as part of a multi-year agreement supporting the creation of a cutting-edge experiential education center in Charlotte, North Carolina. IRCAD NA is set to become the cornerstone of the first research building at "The Pearl," a new innovation district currently under construction in the heart of Charlotte. It will attract thousands of medical professionals from around the world each year for advanced training in the latest surgical techniques and technologies.
LIFEPAK 35, a clinically advanced monitor/defibrillator, reduces caregiver burden and streamlines workflow.1 PORTAGE, Mich., USA, June 4, 2024 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced the launch of LIFEPAK 35 monitor/defibrillator, the latest product in the monitor/defibrillator space, offering advanced technology and built on an intuitive1, modern platform to help advance patient care. Emergency responders and healthcare professionals are facing unprecedented challenges and staff shortages. Seventy-five percent of healthcare worke
Stryker (NYSE:SYK), a global leader in medical technologies, announced the signing of a definitive agreement to acquire all of the issued and outstanding shares of Artelon, a privately held company specializing in innovative soft tissue fixation products for foot and ankle and sports medicine procedures. The acquisition will strengthen Stryker's offerings in the soft tissue fixation segment and highlights Stryker's commitment to providing differentiated solutions for ligament and tendon reconstruction. Artelon's technologies complement and expand the current range of products available to Stryker's foot and ankle and sports medicine specialist customers. Its differentiated synthetic techn
Portage, Michigan, May 09, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.80 per share payable July 31, 2024 to shareholders of record at the close of business on June 28, 2024, representing an increase of 6.7% versus the prior year and unchanged from the previous quarter. About Stryker Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryk
Portage, Michigan, April 30, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2024: First Quarter Results Reported net sales increased 9.7% to $5.2 billionOrganic net sales increased 10.0%Reported operating income margin of 18.5%Adjusted operating income margin(1) increased 80 bps to 21.9%Reported EPS increased 33.1% to $2.05Adjusted EPS(1) increased 16.8% to $2.50 First Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology 11.5 % (0.5) % 12.0 % 0.4 % 11.6
Spineology Inc. ("Spineology" or the "Company"), the leader in ultra-minimally invasive spine surgery, announced today the addition of Emory Rooney as Executive Vice President, Sales. In this role, Rooney will lead U.S. market growth and sales efforts. Rooney comes to Spineology with extensive spine sales experience, having served in Medical Device fields related to spinal implants and navigation for nearly 20 years. "The addition of Emory adds even further conviction about our clear opportunity for growth at Spineology," said Brian Snider, Chief Executive Officer at Spineology. "I have had the opportunity to work with Emory and have seen his impact leading sales teams, building new terri
Portage, Michigan, April 01, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for first quarter of fiscal year 2024 on Tuesday, April 30, 2024. A press release will be issued at approximately 4:05pm ET and available at Stryker - Press Releases that day. The press release will include summary financial information for the company's first quarter of fiscal year 2024, that ended March 31, 2024. Stryker will host a webcast at 4:30pm ET on Tuesday, April 30, to discuss results for its first quarter fiscal year 2024. The webcast can be accessed at Stryker - Events & Presentations. An archive of the webcast will also be available on the company's webs